Hellinger A, Wolter K, Marggraf G, Pentz R, Fritschka E
Department of General Surgery, University of Essen, Germany.
Eur J Clin Pharmacol. 1995;48(1):57-9. doi: 10.1007/BF00202173.
We studied the elimination of amrinone during continuous veno-venous haemofiltration (CVVHF) in three anuric patients after cardiac surgery. The patients had developed low cardiac output followed by acute prerenal failure. Plasma amrinone levels measured by HPLC were fitted to a two-compartment model. We found significant amrinone clearance, with a mean sieving coefficient (S) of 0.44%, which correlates with the protein-unbound, pharmacologically effective fraction of amrinone. The AUC of the arterial plasma concentration-time curve was decreased by 49.8%. All pharmacokinetic parameters showed wide interindividual variation. To ensure the therapeutic effect of amrinone and to avoid toxic adverse effects monitoring of plasma amrinone levels is necessary.
我们研究了三名心脏手术后无尿患者在持续静脉-静脉血液滤过（CVVHF）期间氨力农的清除情况。这些患者出现了低心输出量，随后发展为急性肾前性肾衰竭。通过高效液相色谱法（HPLC）测量的血浆氨力农水平拟合为二室模型。我们发现氨力农有显著清除，平均筛系数（S）为0.44%，这与氨力农未与蛋白结合的药理活性部分相关。动脉血浆浓度-时间曲线的AUC降低了49.8%。所有药代动力学参数均显示出个体间的广泛差异。为确保氨力农的治疗效果并避免毒性不良反应，有必要监测血浆氨力农水平。
